Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 3/20 | 0.55 |
| ▸ | CPA2 | P48052 | 3/20 | 0.55 |
| ▸ | CPA4 | Q9UI42 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 3/20 | 0.51 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.49 |
| ▸ | MMP3 | P08254 | 2/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP12 | P39900 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2633272 | 0.92 | CPA1 (0.56) | CPA1CPA2CPA4ALDH1A1CTSL | |
| SCHEMBL14208695 | 0.91 | CTSL (0.56) | CPA1CPA2CPA4ALDH1A1CTSL | |
| SCHEMBL2632703 | 0.90 | CPA1 (0.61) | CPA1CPA2CPA4ALDH1A1CTSL | |
| SCHEMBL2632731 | 0.88 | CPA1 (0.50) | CPA1CPA2CPA4ALDH1A1CTSL | |
| SCHEMBL2632695 | 0.85 | CPA1 (0.62) | CPA1CPA2CPA4ALDH1A1MMP3 | |
| SCHEMBL10105751 | 0.84 | CPA1 (0.47) | CPA1CPA2CPA4ALDH1A1CTSL | |
| SCHEMBL8972583 | 0.83 | ALDH1A1 (0.64) | CPA1CPA2CPA4ALDH1A1THRB | |
| SCHEMBL12563719 | 0.83 | ALDH1A1 (0.64) | CPA1CPA2CPA4ALDH1A1THRB | |
| SCHEMBL17948648 | 0.83 | CPA1 (0.63) | CPA1CPA2CPA4ALDH1A1MMP2 | |
| SCHEMBL85103 | 0.83 | ALDH1A1 (0.58) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101025-A1 | Compounds For Enzyme Inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101026-A1 | Compounds For Enzyme Inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-8088741-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088741-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, DNPEP, CPN1 | CPA1 142/4885CPA2 276/4885CPA4 314/4885 |
| US-20120101026-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | CPA1 161/4885CPA2 264/4885CPA4 321/4885 |
| US-20120101025-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | CPA1 161/4885CPA2 264/4885CPA4 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.